Maxim Gorbachev, a partner and portfolio manager at RusnanoMedInvest (RMI) speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio about Russia’s and Eastern Europe’s largest venture capital company, specializing in innovative developments in the field of pharmaceuticals and biotechnology.
June 25, 2015, Vedomosti newspaper office will host a FocusForum Conference in Moscow with a leading participation of Leonid Melamed, the Chairman of Team Drive, member of the Board of Directors of NovaMedica, RMI Partners and Doctor Ryadom. The conference’s goal is to gather experts and share ideas and valuable experience in the time of business challenges. In his video interview to Vedomosti, Leonid explained his vision of the company management tasks in the period of uncertainty.
As part of the Panel Discussion “Optimal Strategies and Exit Models for Venture Investors” held during 3rd Moscow International Forum for Innovative Development “Open Innovations” Evgeny Zaytsev shared his experience of various exit models from venture investments in biotech.
In general terms, engagement of private companies in the healthcare system on a competitive basis shall result in the price optimization and improvement of the quality of medical services provided and pharmaceuticals delivered to patients, Leonid Melamed, Chairman of the Board, Team Drive; Member of the Board of Directors, RusnanoMedInvest and NovaMedica said on Friday at St. Petersburg SPIEF2014.
Brian Dovey, Partner, Domain Associates LLC (one of the first venture capital firms to exclusively invest in the life sciences sector) - speaking about VC (Rusnanotech 2011)
Leonid Melamed: Isolated oases of narrowly focused innovation in life sciences are not the way forward for Russia and represent a temporary fix at best – what is needed to drive truly transformational change are fully-integrated life sciences innovation clusters supported by an ecosystem of research and development, finance and other key success factors and specialized skill sets
Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.
24 March 2017
23 March 2017